Clinical Neuroscience Solutions, Inc.
Clinical Neuroscience Solutions, Inc.
Memphis, Tennessee, United States7 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD | attention deficit hyperactivity disorder, inattentive type, neurodevelopmental disorder, oppositional defiant disorder, psychiatric disorder | Recruiting | Phase 4 | 2026-10-05 | NCT04781140 | |
| A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage) | anxiety disorder, generalized anxiety disorder, psychiatric disorder | Active, not recruiting | Phase 3 | 2026-09-25 | NCT06741228 | |
| A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults | Chronic Migraine; Episodic Migraine | Active, not recruiting | Phase 2 | 2026-09-08 | NCT06625060 | |
| A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder | depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Recruiting | Phase 3 | 2026-08-03 | NCT06775379 | |
| Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder | depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Recruiting | Phase 2 | 2026-08-03 | NCT06547489 | |
| Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) | attention deficit hyperactivity disorder, inattentive type, neurodevelopmental disorder, oppositional defiant disorder, psychiatric disorder | Active, not recruiting | Phase 3 | 2026-07-15 | NCT02736656 | |
| Continuation Protocol for Obstructive Sleep Apnea (OSA) | Apnea, Dyssomnias, Respiration Disorders, Sleep Disorders, Intrinsic, nervous system disorder, obstructive sleep apnea syndrome, respiratory system disorder, sleep apnea syndrome, sleep-wake disorder | Enrolling by invitation | Phase 3 | 2025-05-13 | NCT06566820 |